NR1D1 and glioblastoma: Addition of the REV-ERBα antagonist SR8278 [56] increased FABP7 expression (Fig. S3A) and migration of the cells compared to the solvent control DMSO, indicating that suppression of REV-ERBα had a positive influence on the migration properties of U-251 MG glioblastoma cells (Fig. 7A, B).